Dicerna Pharmaceuticals announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has recommended designating DCR-PHXC, the Company’s lead GalXC product candidate, as an orphan medicinal product for the treatment of primary hyperoxaluria (PH) in the European Union (EU). The European Commission (EC) is expected to review the COMP opinion and issue a final…